glp 1 dual agonist Tirzepatide, a GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction | Cardiovascular Diabetology GLP-1 receptor agonists | How

Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors: Are They All the Same

These changes were associated with elevated circulating levels of advanced glycation end products (AGEs), with kidney dysfunction partially mitigated by deletion of the receptor for AGEs ( Ager ) in Glp1r / mice

The boxed warning also mentions the risk of pancreatitis and that the medication is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) and patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

Tissue factor-protease-activated receptor 2 signaling promotes diet-induced obesity and adipose inflammation

Muller TD, Finan B, Bloom SR, D'Alessio D, Drucker DJ, Flatt PR, Fritsche A, Gribble F, Grill HJ, Habener JF, Holst JJ, Langhans W, Meier JJ, Nauck MA, Perez-Tilve D, Pocai A, Reimann F, Sandoval DA, Schwartz TW, Seeley RJ, Stemmer K, Tang-Christensen M, Woods SC, DiMarchi RD, and Tschop MH